comparing results for 3-drug and 2-drug regimens in relapsed/refractory myeloma
Published 6 years ago • 69 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
4:30
triplet regimens for relapsed multiple myeloma
-
1:02
should frontline myeloma treatment include a 3- or 4-drug regimen?
-
21:22
multiple myeloma: combination therapy for relapsed/refractory patients
-
3:25
what are the newest drugs and treatments for relapsed and refractory myeloma?
-
2:04
pomalidomide-based triplets improve responses in relapsed/refractory multiple myeloma
-
41:11
multiple myeloma: what new patients need to know | the patient story
-
5:43
what is a celmod? how is it different from and imid?
-
58:07
managing side effects - multiple myeloma
-
5:53
role of 4-drug regimens in treatment of multiple myeloma
-
3:44
phase iii data for relapsed/refractory myeloma
-
2:23
identifying treatment regimens for patients with multiple myeloma
-
2:55
dr. richardson on isatuximab triplet regimen in relapsed/refractory myeloma
-
1:00
new treatment regimens used to provide maximum benefit in multiple myeloma
-
9:50
treatment for relapsed and refractory multiple myeloma
-
1:02:15
when and how you become refractory to a drug and how to find the best next treatment
-
9:56
ide-cel vs standard regimens for high-risk multiple myeloma: karmma-3 analysis | asco 2023
-
20:58
management of a fit patient: induction, which one to choose, 3 or 4 drugs
-
25:25
icaho19 - multiple myeloma session: relapsed/refractory myeloma
-
5:45
case 3: treatment for relapsed myeloma with 17p deletion
-
5:46
selecting a treatment regimen in r/r multiple myeloma
-
26:29
treatment for relapsed myeloma, fraility, and drugs in development
-
3:05
individualizing treatments in multiple myeloma